VisualDx
VisualDx · Point of care + education · SaaS/web
Clinical Evidence & Decision Support
Clinical decision support with the world's largest curated medical image library for diagnosis assistance; two decades of deployment history in hospitals and med schools.
Evidence at a glance
Freshness, source-checked counts, confidence and gate results below reflect the frozen evidence snapshot through . A later editorial review does not update these results.
- Stated intended users
- Hospitals, health systems, medical schools
- Documentary gate at snapshot
- Failed
- Scenario match
- No evaluated buying scenario currently covers this product
- Comparability
- Not yet comparable in this scenario
- Decision readiness at snapshot
- HISTORICAL — Research only
- Documented evidence at snapshot
- 0 of 2 evidence claims source-checked · confidence Low
- Critical unknowns
- scaled production deployment · documented economic outcomes
- Latest checked-source retrieval in snapshot
- not yet measured
Expand each claim to inspect its source, dates and recorded verification status.
peer reviewed studyJournal of Investigative Dermatology study (Dulmage et al., 2021;141:1230-1235, doi 10.1016/j.jid.2020.08.027) of VisualDx's point-of-care A…2021-06-15
Exact claim. Journal of Investigative Dermatology study (Dulmage et al., 2021;141:1230-1235, doi 10.1016/j.jid.2020.08.027) of VisualDx's point-of-care AI system found 'The AI system achieved an accuracy of 68% in determining the single most likely morphology from the test image bank', while primary care physicians scored 36% without aids and 68% with a visual guide (P < 0.001); on 222 images across Fitzpatrick skin types the AI achieved 70% accuracy in Fitzpatrick I-III and 68% in Fitzpatrick IV-VI (P = 0.79).
- Source
- doi.org
- Type
- peer reviewed study
- Published
- 2021-06-15
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- evidence_strength
- Score contribution
- Feeds evidence strength
Peer-reviewed. Check population, setting, and applicability to your workflow before generalizing.
Open doi.orgpeer reviewed studyCluster-randomized controlled trial in J Med Libr Assoc (2019 Apr 1;107(2):151-162, doi 10.5195/jmla.2019.581) evaluated VisualDx as a clini…2019-04-01
Exact claim. Cluster-randomized controlled trial in J Med Libr Assoc (2019 Apr 1;107(2):151-162, doi 10.5195/jmla.2019.581) evaluated VisualDx as a clinical evidence technology for skin problems in primary care: 'Thirty-two PCPs and 433 patients participated', and time from index visit to skin problem resolution was similar in both groups (hazard ratio=0.92; 95% CI 0.70, 1.21; p=0.54).
- Source
- pmc.ncbi.nlm.nih.gov
- Type
- peer reviewed study
- Published
- 2019-04-01
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- evidence_strength
- Score contribution
- Feeds evidence strength
Peer-reviewed. Check population, setting, and applicability to your workflow before generalizing.
Open pmc.ncbi.nlm.nih.govVerified provider experience is not yet publishable. Fewer than five independent provider organizations have contributed eligible reviews. Reviewer mode is off. Experience never changes documentary scoring, freshness, or rank.
Buyer lenses — evidence-backed bands at snapshot (not a 0–100 rank)
Deployment, integration, data handling at snapshot
- Integration maturity
- live — Listed on an EHR marketplace/partner program — live distribution.
- EHR path
- Epic App Orchard listing, UpToDate/point-of-care links
- FHIR / API
- UNKNOWN
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- SSO
- Supported
- PHI / BAA
- No PHI storage by design
- Security attestations
- SOC 2
- FDA status
- UNKNOWN
Why unknown
Why. No FDA listing found for this product's functions in the tracked category.
What would close it. An FDA 510(k)/De Novo listing, or a clear statement that no regulated function is claimed.
- Pricing
- Not publicly listed
Technical provenance
snap_36bba25c577cbb44 · Evidence cutoff: 2026-08-27T04:05Z · Snapshot generated: 2026-10-21T19:39Z · build ffbf5c3
Forecast calibration is not in the public snapshot — shown as UNKNOWN rather than read from SQLite.
Known limitations
- Deployment traction is UNKNOWN.
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- Economic value evidence is UNKNOWN.
Why unknown
Why. No independently verifiable ROI claim (peer-reviewed, audited case, or independent benchmark) is on file.
What would close it. An audited implementation report or peer-reviewed study with payback/throughput numbers.